|
Antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure1
- Ranexa increases blood pressure by approximately 10 to 15 mm Hg in patients with severe renal impairment, and blood pressure should be monitored regularly in such patients
Ranexa has been shown to prolong the QTc interval in a dose-related manner. While the clinical significance of the QTc prolongation in the case of Ranexa is unknown, other drugs with this potential have been associated with torsades de pointes-type arrhythmias and sudden death.
Ranexa is contraindicated in patients with pre-existing QT prolongation; with hepatic impairment (mild, moderate, or severe); on QT- prolonging drugs; on potent and moderately potent CYP3A inhibitors, including diltiazem.
Effects on Rate-Pressure Product Compared with Placebo2
Hemodynamic effects
- Minimal changes in mean heart rate (<2 bpm) and systolic blood pressure
(<3 mm Hg) were observed in patients with chronic angina in controlled studies
- Similar results were observed in subgroups of patients with CHF NYHA
Class I or II, diabetes or reactive airway disease, and in elderly patients
- Ranexa increases blood pressure by approximately 10 to 15 mm Hg in
patients with severe renal impairment, and blood pressure should be
monitored regularly in such patients
|
